Analyst Recommendation Trends
Wall Street analyst consensus for ARWR over the last few months:
Latest ARWR News
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
Arrowhead (ARWR) targets sHTG with plozasiran vs. Ionis, showing 79â81% TG cuts and strong liquidity. Read here for a detailed investment analysis.
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
PASADENA, Calif., September 29, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs t
RNAi drug specialist ADARx raises $446M IPO
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop.
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
Stocks slid as the 10-year Treasury yield hit a 19-year high on blowout PMI data; cybersecurity stocks bucked the selloff.
These ‘Moonshot’ Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting interim Phase 1/2a data for ARO-DIMER-PA, its dual RNA interference candidate targeting atherosclerotic cardiovascular disease due to mixed hyperlipidemia. Arrowhead Pharmaceuticals has been volatile around the interim ARO-DIMER-PA update, with the share price down 19.76% over the past week and 25.65% over the past month. However, the 1 year total shareholder return of 116.62% and 3 year total shareholder return of...
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Early Dimer Data
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disord
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) H.C.
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. Hyperlipidemia is defined by an excess of fats, or lipids—such as cholesterol and triglycerides—in the blood. Read Also: Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat Interim ARO-
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.
FDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsDr.
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif., September 15, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:55 AM EDTCompany ParticipantsAndy...
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108
Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) 2026 Meeting.
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Perry's liquidity event comes as the Arrowhead stock price surged.
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) presented detailed results from the randomized, double-blind, placebo-controlled Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia. Four quarterly 25-mg doses of plozasiran produced median triglyceride reductions of 79% and 81% at Month 12, compared with approximately 27% for placebo in each study. A prespecified pooled analysis showed […]
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Ionis Pharmaceuticals, Inc. faces significant setbacks after initial optimism, with shares dropping sharply from 52-week highs. Read more on IONS stock here.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
PASADENA, Calif., September 03, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-18 | PERRY MICHAEL S | -11,600 | $87.3 | $1,012,680 |
| 2026-08-18 | OLUKOTUN ADEOYE Y | -2,000 | $86.96 | $173,920 |
| 2026-05-12 | Lu Hongbo | -2,970 | $76.88 | $228,334 |
| 2026-04-23 | Hamilton James C | -10,000 | $75 | $750,000 |
| 2026-04-22 | Apel Daniel Joseph | -8,730 | $71.92 | $627,862 |
| 2026-04-22 | Apel Daniel Joseph | -1,157 | $70.45 | $81,511 |
| 2026-04-22 | Apel Daniel Joseph | -3,208 | $70.11 | $224,913 |
| 2026-03-05 | Hamilton James C | -10,000 | $64.19 | $641,900 |
| 2026-01-06 | Apel Daniel Joseph | +75,000 | - | - |
| 2026-01-06 | Hamilton James C | +75,000 | - | - |
| 2026-01-06 | O'Brien Patrick | +75,000 | - | - |
| 2026-01-06 | O'Brien Patrick | -440 | - | - |
| 2026-01-06 | O'Brien Patrick | -440 | - | - |
| 2026-01-06 | O'Brien Patrick | -540 | - | - |
| 2026-01-06 | O'Brien Patrick | -540 | - | - |
| 2026-01-06 | O'Brien Patrick | -540 | - | - |
| 2026-01-05 | O'Brien Patrick | -46 | $68 | $3,128 |
| 2026-01-05 | O'Brien Patrick | -2,336 | $64.04 | $149,597 |
| 2026-01-05 | O'Brien Patrick | -5,873 | $62.91 | $369,470 |
| 2026-01-05 | O'Brien Patrick | -900 | $62.25 | $56,025 |
| 2026-01-05 | O'Brien Patrick | -600 | $61.12 | $36,672 |
| 2026-01-05 | O'Brien Patrick | -313 | $68 | $21,284 |
| 2026-01-05 | O'Brien Patrick | -900 | $66.01 | $59,409 |
| 2026-01-05 | O'Brien Patrick | -2,700 | $64.44 | $173,988 |
| 2026-01-05 | O'Brien Patrick | -11,842 | $63.84 | $755,993 |
| 2026-01-05 | O'Brien Patrick | -13,451 | $62.96 | $846,875 |
| 2026-01-05 | O'Brien Patrick | -6,164 | $62.23 | $383,586 |
| 2026-01-05 | O'Brien Patrick | -4,368 | $61.2 | $267,322 |
| 2026-01-05 | Hamilton James C | -309 | $68 | $21,012 |
| 2026-01-05 | Hamilton James C | -437 | $65.97 | $28,829 |
| 2026-01-05 | Hamilton James C | -1,200 | $64.49 | $77,388 |
| 2026-01-05 | Hamilton James C | -12,711 | $63.95 | $812,868 |
| 2026-01-05 | Hamilton James C | -14,792 | $63.01 | $932,044 |
| 2026-01-05 | Hamilton James C | -6,090 | $62.28 | $379,285 |
| 2026-01-05 | Hamilton James C | -4,625 | $61.24 | $283,235 |
| 2026-01-02 | Anzalone Christopher Richard | -5,771 | $66.39 | $383,137 |
| 2026-01-02 | Anzalone Christopher Richard | -7,416 | $65.88 | $488,566 |
| 2025-12-31 | O'Brien Patrick | -560 | - | - |
| 2025-12-31 | O'Brien Patrick | -560 | - | - |
| 2025-12-31 | O'Brien Patrick | -560 | - | - |
| 2025-12-31 | O'Brien Patrick | -560 | - | - |
| 2025-12-31 | O'Brien Patrick | -560 | - | - |
| 2025-12-29 | Anzalone Christopher Richard | -16,545 | - | - |
| 2025-12-29 | Anzalone Christopher Richard | -35,181 | - | - |
| 2025-12-29 | Anzalone Christopher Richard | -16,545 | $68.69 | $1,136,476 |
| 2025-12-29 | Anzalone Christopher Richard | -35,181 | $69.33 | $2,439,099 |
| 2025-12-29 | Anzalone Christopher Richard | +16,545 | $6.15 | $101,752 |
| 2025-12-29 | Anzalone Christopher Richard | +35,181 | $6.15 | $216,363 |
| 2025-12-26 | Ferrari Mauro | -7,530 | $70 | $527,100 |
| 2025-12-22 | Anzalone Christopher Richard | -2,574 | $68.85 | $177,220 |
| 2025-12-22 | Anzalone Christopher Richard | -10,012 | $68.33 | $684,120 |
| 2025-12-19 | Vakiener Victoria | -1,960 | $68.39 | $134,044 |
| 2025-12-19 | Vakiener Victoria | -5,281 | $67.97 | $358,950 |
| 2025-12-19 | Vakiener Victoria | -2,799 | $66.63 | $186,497 |
| 2025-12-19 | Waddill William D. | -500 | $68.53 | $34,265 |
| 2025-12-19 | Waddill William D. | -5,451 | $68.01 | $370,723 |
| 2025-12-19 | Waddill William D. | -2,416 | $66.66 | $161,051 |
| 2025-12-19 | Anzalone Christopher Richard | -1,319 | $68.48 | $90,325 |
| 2025-12-19 | Anzalone Christopher Richard | -8,147 | $68.01 | $554,077 |
| 2025-12-19 | Anzalone Christopher Richard | -3,979 | $66.67 | $265,280 |
| 2025-12-19 | OLUKOTUN ADEOYE Y | -827 | $68.48 | $56,633 |
| 2025-12-19 | OLUKOTUN ADEOYE Y | -6,083 | $68.04 | $413,887 |
| 2025-12-19 | OLUKOTUN ADEOYE Y | -3,090 | $66.7 | $206,103 |
| 2025-12-17 | Anzalone Christopher Richard | -1,981 | $66.3 | $131,340 |
| 2025-12-17 | Anzalone Christopher Richard | -982 | $65.53 | $64,350 |
| 2025-12-17 | Anzalone Christopher Richard | -35,750 | $64.51 | $2,306,233 |
| 2025-12-17 | Anzalone Christopher Richard | -46,287 | $63.55 | $2,941,539 |
| 2025-12-16 | Vakiener Victoria | +7,819 | - | - |
| 2025-12-16 | Lu Hongbo | +7,819 | - | - |
| 2025-12-16 | Waddill William D. | +7,819 | - | - |
| 2025-12-16 | Ferrari Mauro | +7,819 | - | - |
| 2025-12-16 | PERRY MICHAEL S | +7,819 | - | - |
| 2025-12-16 | OLUKOTUN ADEOYE Y | +7,819 | - | - |
| 2025-12-16 | INGRAM DOUGLAS S | +7,819 | - | - |
| 2025-12-16 | Anzalone Christopher Richard | -3,221 | $67.87 | $218,609 |
| 2025-12-16 | Anzalone Christopher Richard | -166 | $66.77 | $11,084 |
| 2025-12-16 | Anzalone Christopher Richard | -1,300 | $65.77 | $85,501 |
| 2025-12-16 | Anzalone Christopher Richard | -1,000 | $64.96 | $64,960 |
| 2025-12-16 | Anzalone Christopher Richard | -6,661 | $64.29 | $428,236 |
| 2025-12-16 | Anzalone Christopher Richard | -8,476 | $62.94 | $533,479 |
| 2025-12-16 | Anzalone Christopher Richard | -14,095 | $62.12 | $875,581 |
| 2025-12-16 | Anzalone Christopher Richard | -10,963 | $61.25 | $671,484 |
| 2025-12-16 | Anzalone Christopher Richard | -8,416 | $60.51 | $509,252 |
| 2025-12-15 | Anzalone Christopher Richard | -8,147 | $69.96 | $569,964 |
| 2025-12-15 | Anzalone Christopher Richard | -21,321 | $69.28 | $1,477,119 |
| 2025-12-15 | Anzalone Christopher Richard | -100,532 | $68.67 | $6,903,532 |
| 2025-12-12 | Anzalone Christopher Richard | +180,000 | - | - |
| 2025-12-05 | PERRY MICHAEL S | -16,250 | $61.03 | $991,738 |
| 2025-11-28 | Ferrari Mauro | -8,750 | $56.39 | $493,413 |